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ABSTRACT 
Low Venous Tone (LVT) is defined as impaired venous return which results in lower limb 
symptoms (Turpie, 2011). Symptoms of LVT include oedema, pruritispruritus, muscle cramps, 
weakness of the leg, pain and brown pigmentation of the skin (hemosiderin) (Guyton and Hall, 
2006); venous ulceration and gangrene are related symptoms of LVT (Webster and Thomson, 
2011). Conventional treatment may involve surgery, compression stockings, laser therapy, 
sclerotherapy and venoactive drugs; which are aimed at improving the appearance of varicose 
veins and decreasing pain and swelling.  The combination complementary medicine of Red Vine 
(360 mg), Butcher’s Broom (35 mg), Horse Chestnut (60 mg) and Vitamin B6 (3.2 mg) is an 
over-the counter herbal preparation, used to treat the symptoms associated with CVI.  Studies 
done on each of the constituents show efficacy in improving blood circulation, thereby 
alleviating symptoms associated with venous stasis.   The different extracts improve venous tone 
and blood circulation;   however there are no studies on the complex to evaluate efficacy on the 
quality of life of affected females. 
 
The aim of the study was to determine the effect of a combination complementary medicine 
consisting of Red Vine leaf extract, Butcher’s Broom root extract, Horse Chestnut seed extract 
and Vitamin B6 on the quality of life in females with perceived LVT according to the CEAP C1-
C4 classification using the CIVIQ-20 questionnaire, a valid and reliable tool. 
This was a randomizedrandomised, double-blind, 12 -week study conducted at the Homoeopathy 
Health Centre at the University of Johannesburg, Doornfontein campus. A sample of thirty three 
female participants (aged between 30 and 55 years) completed the study and the sample was 
shared with another master’s student Fayrooz Karriem who investigated “The effects of a 
combination complementary medicine on venous tone”. Forty one participants were screened and 
enrolled in the study using advertisement. The research sample was divided into two groups, 
according to matched pairs by age and severity of pain, at the initial consultation. Participants 
were recruited between the ages of 30 to 55 years and sub-classified as either 30-40 years or 41-
55 years. Their perceived pain severity was recorded and rated and also sub-classified as mild or 
moderate-to-severe using the Clinical Severity Score questionnaire (Appendix G). Participants 
were then either allocated medication A or medication B. This was to ensure that the groups 
were as similar as possible at the start of the study. Participants in group A received placebo 
capsules which contained starch amyral white, di calcium phosphate DC and magnesium stearate 
fine as non-active ingredients and participants in group B received capsules that contained the 
active ingredients 360mg of Red Vine leaf extract (Vitis vinifera), 60mg of Horse Chestnut seed 
extract (Aesculus hippocastanum), 35mg of Butcher’s Broom root extract (Ruscus aculeatus) and 
3,2mg of Vitamin B6 (Pyridoxine). 
 
At the first consultation, participant went through a screening test for eligibility to participate in 
the study. Participants that were eligible to take part in the study underwent a physical 
examination which included vital signs and examination procedure for LVT. Participants were 
asked to fill in the CIVIQ-20 questionnaire with the assistance of the researcher. Copyright 
clearance for the use of the CIVIQ-20 questionnaire was granted.  At the end of the first 
consultation participants were given either the combination complementary medicine capsules or 
placebo capsules and were advised to start taking the capsules every morning with a glass of 
water. During the follow up appointments, a physical examination was conducted and 
participants filled in the CIVIQ-20 questionnaire and given capsules for the month, except at the 
last appointment in week 12. 
 
All data collected from the questionnaire was statistically analysed with the assistance of a 
statistician at Statkon, UJ. Normality tests were done using the Shapiro-Wilk test. The 
comparison within the groups was done using the Friedman test (intra-group analysis) and 
difference over time was done using the Wilcoxon post hoc test. The Mann-Whitney U test was 
used for comparisons between groups (inter-group analysis) (De Klerk, 2016). 
 
Normality tests were conducted within the control and the experimental groups using the 
Shapiro-Wilk test. A bell-shaped curve occurs when the variables in either group are normally 
distributed, whereas for variables that are not normally distributed, the curve would not be bell-
shaped. When using the Shapiro-Wilk test a p-value of ≥ 0.05 indicates normally distributed 
variables and a p-value < 0.05 indicates variables that are not normally distributed (De Klerk 
2016). 
 
The CIVIQ-20 questionnaire was divided into four parts (pain, physical, social and 
psychological outcome measure). According to the Friedman test both the control and 
experimental groups showed a statistically significant decrease in pain outcome measure over the 
12-week study period, however the Wilcoxon post-hoc using the Bonferroni adjustment found no 
statistical decrease in the control group when comparing pain as an outcome measure from week 
1 to week 12. The Mann-Whitney test at week 8 and week 12 showed a significant difference 
between the control group and the experimental group for the pain outcome measure. The 
difference between the groups indicates amelioration in the treatment group. 
The Friedman test indicated that the control group had a statistically insignificant decrease in 
overall physical outcome measures over the 12-week of study. The experimental group had a 
statistically significant decrease over the 12  weeks. The post hoc test using the Bonferroni 
adjustment shows a statistically significant decrease in the experimental group at week 8 and at 
week 12. For physical outcome measures there was no statistically significant difference between 
the control and experimental group at week 4 and week 8, however a statistically significant 
difference between the groups was seen at week 12.  
 
The Friedman test indicated that the control group had an insignificant decrease in social 
outcome measure over the 12 week.  The experimental group had an overall significant 
improvement in social outcome measure. At week 12, inter-group analysis showed a statistically 
significant difference between the control and experimental group for the social outcome 
measure. 
 
Both the control and experimental groups showed a statistically significant decrease in 
psychological outcome measure over the 12-week study period using the Friedman test. 
However, the Bonferroni adjustment showed that the significant difference in the control group 
only occurred in the fourth and eighth week when compared to initial consultation. Inter-group 
analysis for psychological outcome measure showed no significant difference between the 
control group and the experimental group throughout the 12-week study. 
 
It can be concluded that the combination complementary medicine is more effective than placebo 
in improving the quality of life of females with LVT. However, further research is warranted to 
qualify improvement and validate these findings  
 
 
 
 
 
 
  
 
2. INTRODUCTION 
Low Venous Tone (LVT) is defined as impaired venous return which results in lower limb 
symptoms that include pain, swelling and dermatologic changes (Turpie, 2011). 
LVT affects both males and females, but is more prevalent in females due to the vascular dilation 
effect of progesterone (Lenković et al., 2009). The predisposing factors include female gender, 
long periods of standing, decreased physical activity, obesity, poor nutrition, metabolic 
syndrome, tight and restrictive clothing as well as advanced age, constipation, pregnancy and 
ascites. LVT is defective venous return, causing lower limb pain, oedema and dermatological 
changes.  It is caused by disorders that result in increased venous pressure (Turpie, 2011).   
Blood flows from the heart to arteries, capillaries and returns to the heart via venules and veins.  
The flow throughout the body is determined by the heart rate as well as the pressure within a 
blood vessel.  Arteries have thicker muscle walls compared to veins therefore veins distend more 
and store more blood under low pressure compared to arteries (Meissner et al., 2007).  
Approximately 75% of total blood volume is in the veins.  Blood flow through the saphenous 
system of veins in lower extremities is aided by the contraction of the calf muscles, the 
gastrocnemeusgastrocnemius and soleus, and these veins have valves that permit one-way flow 
of blood towards the heart.  The compliance of veins is 24 times that of a corresponding artery 
because it is 8 times more distensible and has a volume 3 times greater; which therefore makes 
blood stasis in veins easy (Guyton and Hall, 2006).   
When a person stands or sits still for a long time, the venous pumps (contraction of the 
gastrocnemeusgastrocnemius and soleus muscles) do not function optimally.  The pressure in the 
veins reaches full gravitational value in less than 30 seconds and the capillary pressure rises 
causing oedema and decreased blood volume inside the vessel.  Eczema, itching and induration 
of the skin are due to prolonged oedema; and brown pigmentation (hemosiderin) is due to 
haemolysis of stagnant red blood cells (Guyton and Hall, 2006).  Muscle cramps, pain and 
weakness; venous ulceration and gangrene are related symptoms of CVI (Webster and Thomson, 
2011). 
Treatment for chronic venous insufficiency is aimed at relieving the physical discomfort and 
improving the appearance of the legs. Treatment includes surgery, sclerotherapy, compression 
stocking, analgesics and anti-diuretics. Surgery and sclerotherapy are invasive procedures aimed 
at improving the appearance of the limbs.   The adverse effect of surgery is that it has poor long-
term results because the varicosities reoccur and regardless of treatment, new varicose veins 
occur and treatment must therefore be maintained indefinitely.  Surgery (ligation and stripping) 
also increases chances of developing deep vein thrombosis (DVT) and might cause loss of 
sensation in the limb.  During sclerotherapy, the veins are fibrosed and occluded using an 
irritant, sodium tetradecyl sulphate.  The negative effect is that overtime, the veins recannulate.  
The compression stocking helps with decreasing pain and oedema, but most females are not 
comfortable using them because they cause pruritispruritus and contact dermatitis.  Compliance 
therefore becomes a problem. The stocking is also complicated because a perfect fit needs to be 
obtained for it to be effective and it needs constant size adjustment as oedema decreases 
(Palfreyman and Michaels, 2009; Sandison, 2013).   
Venavine Intensive® is a self-help product manufactured by Nativa (Pty) (Ltd).  Venavine 
Intensive® is a capsule containing 360mg Red Vine Leaf Extract (Vitis vinifera), 35mg 
Butcher’s broom root extract (Ruscus Aculeatus), 60mg Horse chestnut seed extract (Aesculus 
hippocastanumHippostanum) and 3,2mg vitamin B6 (Pyridoxine).  The red vine leaf extract has 
more than 200 identified constituents with flavoniodsflavonoids being quantitatively important 
constituents.  FlavinoidsFlavonoids were traditionally used for their astringent and homeostatic 
effects for the treatment of diarrhoea, bleeding, varicose veins, haemorrhoids and other venous 
ailments.  In more recent years, the flavonoids have been used in venous disease for the 
microcirculation effect (Chinou and Garcia-Llorente, 2010).     
 
3. MATERIALS AND METHODS 
3.1 Research design 
This was a double-blind, placebo-controlled study with 33 female participants completing the 
study over a period of 12 weeks. The research sample was shared with another Master’s student 
Fayrooz Karriem who investigated “The effects of a combination complementary medicine on 
venous tone”. 
3.2 Research Sample 
Participants were recruited using advertisement at the University of Johannesburg. Forty one 
participants were recruited. Thirty three participants completed the 12 week study with 18 
participants in the treatment group and 15 participants in the control group. The participants were 
aged between 30 and 55 years. 
3.3 Inclusion criteria 
Participants were able to take part in the study if they were: 
 Female; 
 Between ages of 30 to 55 years; 
 Experiencing at least three symptoms related to LVT CEAP C1-C4, which included 
varicose veins, tired or heavy legs, pain in the legs, tingling calves, venous oedema, 
induration of the legs, brown discolouration of the legs, skin changes such as erythema of 
the legs; and 
 Symptoms were aggravated by walking/standing and symptoms were ameliorated by rest 
and limb elevation. 
 
 
 
3.4 Exclusion Criteria 
 
  Pregnant or lactating;  
 On chronic medication for cardiovascular disorders; 
 Had any chronic diseases that were not sufficiently managed; 
 Experiencing CEAP C5-C6 of LVT, including venous ulceration (Appendix E); 
 Were on Warfarin or blood thinning medication; 
 Had any liver or kidney pathologies; 
 Were hypersensitive to any/all herbal extracts; 
 On any treatment (herbal or conventional) for LVT; or 
 Using compression stockings or Kinesio Taping therapy. 
 
4. RESULTS 
Data collected using the CIVIQ-20 questionnaire was statistically analysed. The Shapiro-Wilk 
test was used to determine whether the inclusion criteria of age and symptom severity were 
normally distributed between the two groups at the first consultation. This is important as 
participants were divided into two groups, in matched pairs according to age and symptom 
severity. The age in the control group was normally distributed (p=0.174), but in the 
experimental group the age was not considered to be normally distributed (p=0.026). Pain at 
initial consultation in both groups was normally distributed with p-value of 0.274 for the control 
group and a p-value of 0.982 for the experimental group (De Klerk, 2016). The adjusted initial 
mean pain outcome measure for the control group was 12.722 and the adjusted initial mean pain 
outcome measure for the experimental group was 11.667. 
The test revealed that the age between the groups was normally distributed.                                                               
The control group consisted of 18 female participants and the experimental group consisted of 15 
female participants. The mean age for the control group was 43.056 and the mean age for the 
experimental group was 43.133; the median for age was 42.500 for the control group and 47.00 
for the experimental group; and standard deviation was 8.475 for control group and 9.508 for the 
experimental group.     
 
The Friedman test is a non-parametric test used to test significance at three or more points in 
time or under three different conditions using the same sample of participants (Pallant, 2007). 
The Wilcoxon Signed Ranks test divided the data into three interval periods, contrasting data 
collected at consultation one to data collected at consultation two (week 4); data collected at 
consultation one to data collected at consultation three (week 8); and data collected at 
consultation one to data collected at consultation four (week 12). The test contrasts the least p-
value of the three interval periods for each variable against a significance rank of 0.05/3= 
0.0167, to establish statistical significance. The tests contrasts the second least p-value of the 
three interval periods for each variable against a significance rank of 0.05/2= 0.025, to establish 
statistical significance. The tests contrasts the biggest p-value of the three interval periods for 
each variable against a significance rank of 0.05/1= 0.05, to establish statistical significance (De 
Klerk, 2016). 
A Mann-Whitney test is a non-parametric test that is used to compare two population means that 
come from the same population. It is used to test whether two population means are the same or 
not (Statistic Solutions, 2016).  The difference between the groups indicates amelioration in the 
treatment group. 
Pain Outcome Measure 
 
Intra-group Analysis – Friedman Test and Bonferroni Adjustment 
The Friedman test is a non-parametric test used to test significance at three or more points in 
time or under three different conditions using the same sample of participants (Pallant, 2007). 
The pain outcome measure values for both the control and experimental groups for the 12-week 
study period. The first four questions from the CIVIQ-20 related to pain were grouped together; 
each question was given a score from one (no pain outcome) to five (severe pain outcome). The 
mean pain outcome measure for the control group decreased by 1.55 and the mean pain outcome 
measure for the experimental group decreased by 5.60 (when subtracting week 4 from week 1). 
At initial consultation, the mean for control group seemed much higher compared to the 
experimental group due to the different group size; the mean rank however shows a value 
independent of group size. Even though there was a decrease in the recorded pain outcome 
measure for both the groups over 12 weeks, the control group did show a fluctuation of pain 
outcome with an increase from week 8 to week 12 (from 11.00 to 11.17). 
 
According to the Friedman test both the control and experimental groups showed a statistically 
significant decrease in pain outcome measure over the 12-week study period. However the 
Wilcoxon post-hoc using the Bonferroni adjustment (adjusted p-values < 0.0167; and < 0.025; 
and <0.05) found no statistical decrease in the control group when comparing pain as an outcome 
measure from week 1 to week 12 (p = 0.377). The Wilcoxon Signed Ranks test divided the data 
into three interval periods, contrasting data collected at consultation one to data collected at 
consultation two (week 4); data collected at consultation one to data collected at consultation 
three (week 8); and data collected at consultation one to data collected at consultation four (week 
12). The test contrasts the least p-value of the three interval periods for each variable against a 
significance rank of 0.05/3= 0.0167, to establish statistical significance. The tests contrasts the 
second least p-value of the three interval periods for each variable against a significance rank of 
0.05/2= 0.025, to establish statistical significance. The tests contrasts the biggest p-value of the 
three interval periods for each variable against a significance rank of 0.05/1= 0.05, to establish 
statistical significance (De Klerk, 2016).  According to the Wilcoxon test results for the pain 
outcome measure; the experimental group had a consistent trend of amelioration on all three 
intervals (p = 0.035, p = 0.001 and p = 0.001) whilst the control group only showed significance 
at interval one (week 1 to week 4 with p = 0.002). 
 
Inter-group Analysis – Mann-Whitney Test 
A Mann-Whitney test is a non-parametric test that is used to compare two population means that 
come from the same population. It is used to test whether two population means are the same or 
not (Statistic Solutions, 2016).  At week 8 and week 12, the inter-group analysis shows a 
significant difference between the control group and the experimental group for the pain 
outcome measure (p = 0.019 and p = 0.001 respectively). The difference between the groups 
indicates amelioration in the treatment group. 
 
Physical Outcome Measure 
 
Intra-group Analysis – Friedman Test and Bonferroni Adjustment 
Four questions from the CIVIQ-20 questionnaire (questions 5-7 and 9) were related to physical 
limitations due to low venous tone.  Each question was rated from one (not bothered) to a final 
value of five (impossible to do). The mean physical outcome measure for both the control and 
the experimental groups decreased by 0.5 and 3.13 respectively over the 12-week period (when 
subtracting week 12 mean from week 1 mean). The control group’s initial mean physical 
outcome measure is higher than that of the experimental group due to the difference in group 
size; however the difference is corrected in the mean ranks to be independent of size. 
 
The Friedman test indicated that the control group had a statistically insignificant decrease in 
overall physical outcome measures over the 12-week of study with p-value of more than 0.05 (p 
= 0.225). The experimental group had a statistically significant decrease over the 12 weeks with 
a p value less than 0.05 (p = 0.000).  
 
According to the Wilcoxon test results for physical outcome measure, the post hoc test using the 
Bonferroni adjustment shows a statistically significant decrease in the experimental group at 
week 8 (p = 0.004), and at week 12 (p = 0.007) (a p-value less than the adjusted p > 0.016; p > 
0.025). 
 
Inter-group Analysis – Mann-Whitney Test 
For physical outcome measures there was no statistically significant difference between the 
control and experimental group at week 4 and week 8, however a statistically significant 
difference between the groups was seen at week 12 (p = 0.003).  
 
Social Outcome Measure 
 
Intra-group Analysis – Friedman Test and Bonferroni Adjustment 
Three questions from the CIVIQ-20 questionnaire (questions 8, 10 and 11) are related to social 
activity limitations due to low venous tone; each question is scaled from one (not limited or 
bothered) to five (impossible to do). The control group showed an overall decrease of 0.44 over 
the 12 weeks, and the experimental group had an overall decrease of 3.47 for the 12-week study 
period (when subtracting week 12 mean from week 1 mean). The control group social outcome 
measure mean decreased from 6.50 to 6.06 from week 1 to week 12; however when looking at 
week 4 to week 12, it was noted that the initial amelioration (from 6.50 to 5.83) was followed by 
a slight aggravation (from 5.83 at week 4 to 5.89 at week 8, then 6.06 at week 12). And the 
experimental group had a consistent trend of amelioration from week 1 through to week 12.  
 
The Friedman test indicated that the control group had an insignificant decrease in social 
outcome measure over the 12 week period, p = 0.267 (p > 0.05).  The experimental group had an 
overall significant improvement in social outcome measure (p < 0.05), the experimental group 
had a statistically significant decrease on two accounts (week 8 and week 12) recorded using the 
Bonferroni adjustments (p > 0.0167; p > 0.025; and p > 0.05) with p = 0.001 on both accounts. 
 
Inter-group Analysis – Mann-Whitney Test 
At week 12, inter-group analysis shows a statistically significant difference between the control 
and experimental group for the social outcome measure (p = 0.012).  
 
Psychological Outcome Measure 
 
Intra-group Analysis – Friedman Test and Bonferroni Adjustment 
From the CIVIQ-20 questionnaire nine questions (12-20) were measured together with each 
question scaled from one (not at all) to five (absolutely) regarding how the participants were 
psychologically affected by LVT. The mean value for the control group (21.33) at initial 
consultation was greater than that of the experimental group (18.87) because of the group size 
difference. The mean rank showed a corrected value as it is not dependent on the group size 
(3.17 for the control group and 3.23 for the experimental group). The mean psychological 
outcome measure decreased by 3.11 for the control group and decreased by 5.4 for the 
experimental group for the overall 12-week study period. 
 
Both the control and experimental groups showed a statistically significant decrease in 
psychological outcome measure over the 12-week study period using the Friedman test, Asymp. 
Sig (p = 0.030 and p = 0.000 respectively). However, the Bonferroni adjustment showed that the 
significant difference in the control group only occurred in the fourth and eighth week when 
compared to initial consultation (p = 0.012 and p = 0.006 respectively). The overall adjusted p-
value for the control group was 0.081, making it greater than p < 0.0176, p < 0.025 and p < 0.05. 
The adjusted p-value for the experimental group showed a statistically significant decrease at 
week 8 and week 12 (p = 0.012 and p = 0.002) respectively, making it less than p = 0.0176; p = 
0.025; and p = 0.05. The change at week 4 was not statistically significant; p = 0,112, (p > 
0.0176, 0.025 and 0.05). The experimental group’s adjusted mean rank was used to evaluate the 
p-value, hence the p-value at week 4 is insignificant even though the mean at week 4 is less than 
the mean at week 8, and the mean rank shows size independent values. 
 
Inter-group Analysis – Mann-Whitney Test 
 
Inter-group analysis for psychological outcome measure showed no significant difference 
between the control group and the experimental group throughout the 12-week. 
 
 
4.1 Pain outcome measure results 
Table 4.1 Pain outcome measure Friedman test  
 
Control              N 
                          Chi-Square 
                          df 
                          Asymp. Sig. 
Experimental    N 
                          Chi-Square 
                          df 
                         Asymp. Sig  
18 
10.006 
3 
.019 
15 
29.127 
3 
.000 
 
Table 4.2 Wilcoxon test results for pain outcome measure 
 
  
Group 
Control Treatment 
Z P value (2-tailed) Z P value (2-tailed) 
Pain1-Pain 2 -3.072 .002 -2.111 .035
Pain3 - Pain1 -1.282 .200 -3.258 .001
Pain4 - Pain1 -.883 .377 -3.420 .001
 
 4.2 Physical outcome measure results 
Table 4.3 Physical outcome measure Friedman test  
 
Control              N 
                          Chi-Square 
                          df 
                          Asymp. Sig. 
Experimental    N 
                          Chi-Square 
                          df 
                         Asymp. Sig  
18 
4.360 
3 
.225 
15 
18.500 
3 
.000 
 
Table 4.4 Wilcoxon test results for physical outcome measure 
 
  
Group 
Control Treatment 
Z P value (2-tailed) Z P value (2-tailed) 
Phys1-Phys 
2   -.953 .341
Phys3 - 
Phys1   -2.880 .004
Phys4 - 
Phys1   -2.714 .007
 
 
 
4.3 Social outcome measure results 
Table 4.5 Social outcome measure Friedman test 
 
Control              N 
                          Chi-Square 
                          df 
                          Asymp. Sig. 
Experimental    N 
                           Chi-Square 
                           df 
                           Asymp. Sig  
18 
3.952 
3 
.267 
15 
31.795 
3 
.000 
 
Table 4.6 Wilcoxon test results for social outcome measure 
 
  
Group 
Control Treatment 
Z P value (2-tailed) Z P value (2-tailed)
social1-Social 2 
  -1.902 .057
Social3 - 
Social1   -3.351 .001
Social4 - 
Social1   -3.318 .001
 
4.4 Psychological outcome result 
 
4.7 Psychological outcome measure Friedman test  
 
Control         N 
                    Chi-Square 
                    df 
                    Asymp. Sig. 
Experimental    N 
                   Chi-Square 
                   df 
                   Asymp. Sig  
18 
8.943 
3 
.030 
15 
22.160 
3 
.000 
 
 
Table 4.8 Wilcoxon test results for psychological outcome measure 
 
  Group 
Formatted: Font: Times New Roman
Control Treatment 
Z   P value (2-tailed) Z   P value (2-tailed)
Phys1-Phys 2 -2.513 .012 -1.588 .112
Phys3 - Phys1 -2.731 .006 -2.519 .012
Phys4 - Phys1 -1.743 .081 -3.072 .002
 
5. DISCUSSION 
5.1 Pain outcome measure 
The statistical analysis using the Friedman test showed a statistically significant decrease in pain 
for both the control and experimental groups (p = 0.019 and p = 0.000 respectively) for the 12-
week study period. Further post-hoc tests using the Bonferroni adjustment showed that only the 
experimental group had a statistically significant decrease in pain with a p-value of 0.001, which 
is less than the adjusted values of p = 0.0167 and p = 0.025 and p = 0.05. The control group had 
an insignificant decrease over time with an adjusted p-value of 0.377, which was greater than p = 
0.016 and p = 0.025 and p = 0.05). 
 
The Mann-Whitney tests for pain outcome measure showed a significant difference between the 
control group and the experimental group at week 8 and week 12 (p = 0.019 and p = 0.001 
respectively) in favour of the experimental group, therefore the combined complementary 
medicine had a statistically significant effect over placebo. 
The combination complementary medicine consisted of 360mg Red Vine leaf extract, 60mg 
Horse Chestnut seed extract, 35mg Butcher’s Broom root extract and 3.2mg Vitamin B6. The 
three herbs in this combination decrease limb pain associated with low venous tone, thereby 
improving physical activity and mobility; in turn increasing the quality of life in low venous tone 
(Nees et al., 2003; Chinou and Garcia-Llorente, 2010; Kalus et al., 2004, Vanscheidt et al., 
2007; Leach et al., 2006). 
 
5.2 Physical outcome measure 
The statistical analysis for the physical outcome measure using the Friedman test showed an 
overall insignificant decrease for the control group and a significant decrease for the 
experimental group (p = 0.225 and p = 0.000 respectively) during the 12-week study period. 
Further post-hoc testing using the Bonferroni adjustment (p <0.0167, p <0.025 and p <0.05) 
showed a statistically significant decrease in the physical outcome measure for the experimental 
group at week 8 (p =0.004) and at week 12 (p =0.007). This amelioration  coincides with the 
amelioration in pain outcome measure, therefore a decrease in pain means an improved ability to 
participate in physical activities (i.e. improved quality of life, as chronic disease status is 
associated with a decreased quality of life) (Sandison, 2013). 
 
The Mann-Whitney test for inter-group analysis for physical outcome measure showed a 
statistically significant difference between the control group and the experimental group at week 
12 (p = 0.003). 
 
5.3 Social outcome measure 
The first statistical analysis using the Friedman test showed a statistically insignificant decrease 
in the social outcome measure for the control group over the 12-week study period with p-value 
of 0.267 and a statistically significant decrease for the experimental group over the 12 weeks of 
the study with a p-value of 0.000. Both groups had improvement of social outcome measure 
during the study period; however the control group’s amelioration was only seen in week 4 (from 
6.50 at baseline to 5.83 at week 4), then followed by an aggravation of symptoms from week 8 to 
week 12 (5.89 to 6.06 respectively). The experimental group had a consistent trend of 
amelioration throughout the study. Further post-hoc tests using the Bonferroni adjustment 
showed that the experimental group had a statistically significant change over time at week 8 and 
at week 12 (adjusted p-values were all less than p =0.0167 and p =0.025 and p =0.05) with p 
=0.000 at week 8 as well as week 12. This improvement of social outcome measure coincides 
with the improvement in pain and physical outcome measure seen at weeks 8 and 12.  
 
The Mann-Whitney test for inter-group analysis on social outcome measure showed a 
statistically significant difference between the control group and the experimental group at week 
12 (p = 0.012), indicating amelioration in the experimental group 
 
5.4 Psychological outcome measure 
The initial analysis using the Friedman test showed a statistically significant decline in 
psychological outcome measure for both the control and experimental groups (p=0.030 and 
0.000 respectively) over the 12-week study period. Further post-hoc tests using the Bonferroni 
adjustment (p < 0.0167 and p < 0.025 and p < 0.05) over time showed that the statistically 
significant change only occurred at week 4 and week 8 for the control group with p-value of p = 
0.012 and p = 0.006 respectively. This amelioration coincides with the amelioration in pain, 
physical outcome measure and social outcome measure, however the overall adjusted p-value for 
psychological outcome measure over the 12-week study period is 0.081, which is greater than 
the adjusted p-value (<0.0167 and <0.025 and <0.05); therefore psychological outcome measure 
improvement was statistically insignificant over time for the control group. 
 
The experimental group had a statistically significant improvement in psychological outcome 
measure during week 8 and week 12 with adjusted p-value < 0.0167 and 0.025 and 0.05 (p 
=0.012 and p =0.002) respectively. The overall adjusted p-value for experimental group 
psychological outcome measure was 0.002, therefore a statistically significant decline. A decline 
in psychological outcome measure occurred in both groups over time; however the constant 
decline was only seen in the experimental group, whilst the control group had an aggravation 
from week 8 to week 12. 
 
However, the Mann-Whitney test showed no statistically significant difference between the 
control group and the experimental group over the 12 weeks of the study, which means the 
combination complementary medicine did not outperform the placebo for this variable 
 
6. CONCLUSSION 
It can be concluded that the combination complementary medicine showed a statistically 
significant improvement on all four outcome measures of the quality of life. The results of this 
study support the hypothesis that the combination complementary medicine is more effective 
than placebo in improving the quality of life of females with LVT. However, further research is 
warranted to qualify improvement and validate these findings.  
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